Very-long-chain acyl-CoA dehydrogenase (VLCAD) is a major enzyme catalysing the first step in mitochondrial b-oxidation of longchain fatty acids. During analysis of the VLCAD promoter, we discovered that another gene, discs-large-related 4 (DLG4), overlaps VLCAD and is transcribed in the opposite direction. DLG4 encodes postsynaptic density-95 (PSD95) protein, which plays critical roles in the formation and maintenance of synaptic junctions. The transcription start site of the VLCAD gene was determined by primer extension analysis and the overlapping structure of VLCAD and DLG4 was clarified. VLCAD and DLG4 are arranged in a head-to-head orientation on chromosome 17p13, and share a 245 bp overlapping region that contains part of DLG4 exon 1 and the entire exon 1 of VLCAD including 62 bp of protein coding sequence. Despite the overlap of their 5 0 ends, DLG4 and VLCAD exhibit peak mRNA expression in different tissues, suggesting that they are independently regulated at the transcriptional level. Interestingly, VLCAD and DLG4 genes do not overlap in the mouse or Drosophila genomes. q
Introduction
Very-long-chain acyl-CoA dehydrogenase (VLCAD) is the major enzyme catalysing the first dehydrogenation step in the mitochondria b-oxidation of very long chain fatty acids (Strauss et al., 1995; Andresen et al., 1996) . Four enzymes with different chain length specificities participate in the initial step in the mitochondria b-oxidation of straight-chain fatty acids. These are VLCAD, which requires straight-chain acyl-CoA substrates lengths of C 14 -C 20 ; long-chain acyl-CoA dehydrogenase (LCAD); medium-chain acyl-CoA dehydrogenase (MCAD) and short-chain acyl-CoA dehydrogenase (SCAD). Four distinct dehydrogenase deficiencies have been described, with VLCAD deficiency being documented to cause hepatocellular dysfunction, severe lipid accumulation in organs, and cardiac disease, particularly hypertrophic cardiomyopathy .
Human VLCAD cDNA and genomic sequences were reported (Orii et al., 1995; Strauss et al., 1995; Andresen et al., 1996) . The VLCAD gene is about 5.4 kb long, contains 20 exons that encode a 655-amino-acid protein and is located on chromosome 17p13. VLCAD differs from the other three acyl-CoA dehydrogenases in that it is a homodimer of 70 kDa subunits bound to the inner membrane whereas the others are soluble enzymes found in the matrix. Since patients with VLCAD deficiency were first reported (Aoyama et al., 1993; Bertrand et al., 1993) , more than 80 VLCAD mutations have been identified. These include nucleotide substitution, small and gross deletions and insertions, and small insertions/deletions. There is a distinct relationship between the severity of VLCAD deficiency and the nature of the mutations. Severely affected patients have mutations that result in complete loss-of-function, whereas patients with milder phenotypes have mutations that result in residual enzyme activity (Andresen et al., 1999) . Little is currently known about the regulation of VLCAD transcription. In this report, we analysed the 5 0 region of VLCAD and discovered another gene, discs-large-related 4 (DLG4), overlapping VLCAD. DLG4 encodes the postsynaptic density-95 (PSD95) protein (Gomperts, 1996) . PSD95 interacts with both N-methyl-Daspartate (NMDA) receptors and Shaker-type potassium channels and plays an important role in the formation and maintenance of synaptic junction (Stathakis et al., 1999) . DLG4 is positioned in a head-to-head orientation with the VLCAD, such that the 5 0 -untranslated region of DLG4 overlaps with the 5 0 -UTR and a part of the protein-coding region of VLCAD. VLCAD and DLG4 are both widely expressed in adult tissues but each has peak expression in different tissues. Thus, despite their shared 5 0 regions, DLG4
and VLCAD are likely to be differentially regulated at the level of transcription. Consistent with this model, the VLCAD and DLG4 homologs are not overlapping in the mouse and Drosophila genomes.
Materials and methods

Primer extension analysis
Primer extension analysis was performed using the VLCAD specific oligonucleotide primer VL-66R (5 0 -TCCTGCACGCCCACGTCCT-3 0 ), located 66 bp upstream of the inferred VLCAD ATG translation start codon. Total RNA was extracted from HeLa cells using the RNeasy kit (Qiagen) and primer extension performed using AMV reverse transcriptase (Primer Extension System; AMV Reverse Transcriptase Kit, Promega) according to the manufacturer's recommended protocols. Briefly, 5 0 endlabeling reactions were conducted in a 10-ml volume containing 10 pmol VL-66R, 1£ T4 polynucleotide kinase buffer, 30 mCi [g-32 P]ATP and 10 units T 4 polynucleotide kinase. Primer extension reactions were conducted in 20 ml volume containing 10 mg total RNA, 1 pmol 32 P-labeled primer, 2.8 mM sodium pyrophosphate, 1£ AMV buffer and 2 units AMV reverse transcriptase. The transcription start site was mapped by electrophoresis on a 6% denaturing polyacrylamide gel and comparison with a DNA sequencing reaction from the VLCAD promoter using the same primer.
Quantitative real-time RT -PCR analysis
Human multiple tissue cDNA panels, which contain sets of first-strand cDNA, generated from different human tissues were commercially obtained (BD Clontech). Quantitative real time PCR was performed using the following primer sets:
, with the SYBR green PCR kit (Applied Biosystems) in a DNA Engine Opticon -Continuous Fluorescence Detection System (MJ Research). All samples were analysed in duplicate and quantitated by the comparative Ct method for relative quantitation of gene expression, normalized to GAPDH (Livak and Schmittgen, 2001 ).
Results and discussion
Characterization of the 5
0 region and transcription start site of VLCAD gene
The VLCAD gene, located on chromosome 17p13, is about 5.4 kb long and consists of 20 exons and 19 introns (Orii et al., 1995) . A BLAST search of the draft human genome using the VLCAD gene sequence (GenBank: SEG_D78279S) identified a chromosome 17-derived clone HRPC4G17 (GenBank: AC003688) that contains the entire VLCAD gene on its plus strand. This 98-kb PAC clone was sequenced by the Whitehead Institute/MIT center for Genome Research for the human chromosome 17 genome sequencing project. Further analysis of the upstream region of VLCAD gene identified another previously described gene, DLG4 (Stathakis et al., 1997) . The DLG4 gene encompasses approximate 30 kb and is composed of 22 exons. The HRPC4G17 clone contains the first 10 exons of DLG4 gene on its minus strand. Of particular interest is the fact that the 5 0 end of DLG4 gene overlaps with the VLCAD gene and its transcription start site extends to the coding region of VLCAD exon 1 (Fig. 1A) . The genomic structure and transcription start site of DLG4 were reported (Stathakis et al., 1999) . However, the transcription start site of VLCAD was unknown. We therefore conducted primer extension analysis of VLCAD. Total RNA from HeLa cells, which express the VLCAD mRNA (data not shown), was used to define the VLCAD transcription start site. Several groups have characterized the VLCAD cDNA. Only one major transcript was detected in a variety of human tissues and the mRNA size corresponds closely to the size of the VLCAD cDNA sequence Orii et al., 1995; Strauss et al., 1995; Andresen et al., 1996) . The primer used for primer extension analysis is located 66 bp upstream of VLCAD translation start site, within the VLCAD exon 1 and transcription region. Primer extension revealed a single, distinct 113 bp band (Fig. 2) . This indicates that the major VLCAD transcription start site is located 179 nucleotides upstream from the inferred ATG-translation initiation codon of VLCAD. This position is within DLG4 exon 1, 245 nucleotides downstream from its transcription start site (Fig.  1B) .
After clarifying the transcription start site of the VLCAD gene, we found that VLCAD and DLG4 share 245 nucleotides at their 5 0 ends, and are transcribed in opposite directions. The sequence of the overlapping region of VLCAD and DLG4 genes was confirmed by sequencing of a 1 kb genomic PCR fragment obtained directly from human genomic DNA using a primer set that corresponds to both VLCAD and DLG4 (data not shown).
The overlapping gene structure of VLCAD and DLG4 is unusual in the human genome. The N-terminus of the DLG4 gene product, the PSD95 protein, is modified by thioesterlinked palmitate, a 16-carbon saturated fatty acid that targets PSD95 to cell membranes (Topinka and Bredt, 1998 ). PSD95 is a major palmitoylated protein in intact cells and palmitoylation is a critical regulatory mechanism for receptor interactions with PSD95. On the other hand, VLCAD is the major enzyme for the degradation of palmitate during its first step of b-oxidation in vivo. Therefore, the unusual structure of these two genes suggests a possible link between the use of palmitate as an energy substrate and the signal transduction pathway mediated by PSD95.
Tissue specific distribution of VLCAD and DLG4
Human multiple tissue cDNA panels, which contain sets of first-strand cDNA generated from different human tissues were used to investigate the tissue specific distribution of VLCAD and DLG4 by quantitative real-time RT -PCR. Although the overlapping region of VLCAD and DLG4 covers the entire VLCAD exon 1 including 62 bp of coding region, transcription of these two genes is not impaired by their overlap. Both genes can be co-expressed in the same tissues, but exhibit different patterns of maximal expression (Fig. 3) . DLG4 mRNA is most abundant in brain with prominent expression detected in heart, placenta, lung, pancreas, spleen, thymus, testis, ovary and small intestine. In contrast, VLCAD is highly expressed in heart and skeletal muscle with lower levels detectable in placenta and pancreas. Both genes were expressed at lower, but detectable levels in the other tissues examined. We infer from the expression of their mRNAs that these two genes share common regulatory elements but also have distinct tissue-specific elements required for high-level expression.
Computer analysis of the upstream regions of VLCAD and DLG4 genes including their overlapping region was performed using promoter scan II (http://biosci.cbs.umn. edu/software/software.html) and MatInspector 2.2 (http:// transfac.gbf.de/TRANSFAC). This analysis identified two potential TATA-less promoters and potential binding sites for several transcription factors including Sp1, AP-1, AP-2, C/EBP and NF-kB. The computer prediction of VLCAD gene's promoter region and AP-2 binding site are consistent with a published report (Zhou et al., 1999) . Further studies to characterize transcription factors essential for the correct regulation of both these promoters will provide insight into the mechanism governing the regulation of both genes at the transcriptional level.
Evolutionary analysis of VLCAD and DLG4 gene loci
Overlapping genes occur frequently in prokaryotic, viral and mitochondrial genomes but only rarely in most eukaryotic genomes, including the human genome (Shintani et al., 1999) . Since the first two overlapping genes reported by Emi et al. (Emi et al., 1988) , a small number of human overlapping genes have been identified (Ubeda et al., 1999; Faurholm et al., 2001; Dan et al., 2002) . Although a few cases have been reported, anti-parallel overlapping of exons of functional protein coding genes is quite rare (Nicolaides et al., 1995; Herzog et al., 1997; Cooper et al., 1998) .
To investigate the evolution of this overlapping organization, we examined the structure of VLCAD and DLG4 in the draft Drosophila and mouse genomes. The Drosophilagene CG7461 (FlyBase ID: FBgn0034432) that encodes VLCAD is located on chromosome 2R 56C9-56C10. Discs large 1 (FlyBase ID: FBgn0001624), the fly ortholog of the human DLG family is located on the X chromosome at locus 10B11 -10B12. A BLAST search of the mouse genome with VLCAD (XM_126408) and DLG4 (NM_007864) revealed that these genes are both located on chromosome 6 at 11B3 -B4 in a head-to-head orientation. In contrast to the human genes, the mouse genes do not overlap and contain a gap of 3.48 kb between them. This suggests that the VLCAD and DLG4 genes were originally separated but have become co-localized during the course of evolution. Further analysis of the genomic structures of these genes in other organisms (as the genomic sequences become available) will allow one to deduce when this colocalization event occurred during the course of vertebrate evolution.
Conclusion
We identified two overlapping genes VLCAD and DLG4 in the human genome. The transcription start site of VLCAD was determined and it was shown that VLCAD and DLG4 are organized in a head-to-head orientation sharing a 245 bp overlapping region that encompasses part of DLG4 exon 1 and the entire first exon of VLCAD including 62 bp of protein-coding region. Both genes were expressed in all adult tissues examined although sites of peak expression were different. VLCAD and DLG4 exonic sequences do not overlap in the Drosophila or mouse genomes, suggesting that the loss of intergenic sequences happened late in mammalian evolution.
